| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| pt2385 | hypoxia-inducible factor 2 alpha | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of brain[MeSHID:D001932] Von Hippel-Lindau Syndrome[MeSHID:D006623] Recurrence (disease attribute)[MeSHID:D012008] Glioblastoma[MeSHID:D005909] |
NA | phase 2 | unknown |
| pt2385 | hif2-alpha messenger rna | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of brain[MeSHID:D001932] Von Hippel-Lindau Syndrome[MeSHID:D006623] Recurrence (disease attribute)[MeSHID:D012008] Glioblastoma[MeSHID:D005909] |
NA | phase 2 | unknown |
| pt2385 | hif1-alpha messenger rna | NA | Clinical trial target | TTD | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of brain[MeSHID:D001932] Von Hippel-Lindau Syndrome[MeSHID:D006623] Recurrence (disease attribute)[MeSHID:D012008] Glioblastoma[MeSHID:D005909] |
NA | phase 2 | unknown |
| click here to return to the previous page | ||||||||